Peptide data sheet
Retatrutide
GLP-1 · LY3437943
Verdict
promisingThe promising label reflects the strong early human trial data for weight and metabolic endpoints; it is tempered by the fact that retatrutide is still investigational, not FDA-approved, and the research-grade material sold for lab use is not the trial drug.
Quick answer
Retatrutide (LY3437943) is an experimental peptide that acts on three metabolic receptors at once. It is most commonly researched for weight management and blood-sugar outcomes, and unlike many research peptides it has real human trial data. It is still investigational and not FDA-approved; research-grade retatrutide is sold for laboratory research use only.
- Class
- Triple agonist (GIP / GLP-1 / glucagon receptor)
- Half-life
- roughly 6 days (reported), supporting once-weekly research schedules
- FDA status
- Not FDA-approved. Retatrutide is an investigational compound still in clinical trials; research-grade material sold for lab use is intended for laboratory research only.
- WADA banned?
- No
Which form actually works?
Injectable (subcutaneous)
Promising
The form used in the human trials and where essentially all of the research context lives. People report interest here because it matches how the compound was actually studied.
Oral
Unproven
Sometimes asked about by analogy to other metabolic drugs, but retatrutide's human data comes from the injectable form. An oral version is not where the studied evidence sits.